| 25 0.54 (2.21%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.56 |
1-year : | 34.52 |
| Resists | First : | 25.3 |
Second : | 29.56 |
| Pivot price | 23.15 |
|||
| Supports | First : | 23.12 |
Second : | 21.78 |
| MAs | MA(5) : | 24.2 |
MA(20) : | 23.11 |
| MA(100) : | 18.03 |
MA(250) : | 16.45 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 82.3  |
D(3) : | 84.2 |
| RSI | RSI(14): 69.9 |
|||
| 52-week | High : | 25.3 | Low : | 9.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CNTA ] has closed Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.33 - 25.4 | 25.4 - 25.48 |
| Low: | 24.38 - 24.47 | 24.47 - 24.58 |
| Close: | 24.84 - 24.98 | 24.98 - 25.13 |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Mon, 27 Oct 2025
Centessa Pharma (CNTA) president sells $200k in shares - Investing.com
Fri, 24 Oct 2025
Centessa Pharmaceuticals stock hits 52-week high at $24.65 - Investing.com
Tue, 21 Oct 2025
Centessa Pharmaceuticals (CNTA) Stock Analysis: A Biotech Powerhouse with 42% Upside Potential - DirectorsTalk Interviews
Wed, 08 Oct 2025
Are Investors Undervaluing Centessa Pharmaceuticals Plc (NASDAQ:CNTA) By 23%? - 富途牛牛
Tue, 07 Oct 2025
Centessa Pharmaceuticals (CNTA) Stock Analysis: A Biotech Play with 41% Upside Potential - DirectorsTalk Interviews
Wed, 03 Sep 2025
Clinical-Stage Pharma Centessa to Present Latest Developments at Morgan Stanley Healthcare Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 8.506e+007 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 5,510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0611e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 376.1 % |
| Return on Equity (ttm) | -29 % |
| Qtrly Rev. Growth | 1.5e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -46.45 |
| EBITDA (p.s.) | 9.55414e+006 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -144 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.54 |
| Price to Cash Flow | 15.21 |
| Dividend | 0 |
| Forward Dividend | 5.2e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|